Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 2Completed 2Unknown 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Genitourinary 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 47Breast Neoplasms 39Ovarian Neoplasms 35Triple Negative Breast Neoplasms 24Endometrial Neoplasms 20Stomach Neoplasms 19Squamous Cell Carcinoma of Head and Neck 17Fallopian Tube Neoplasms 17Lung Neoplasms 16Esophageal Squamous Cell Carcinoma 14Parkinson Disease 4, Autosomal Dominant Lewy Body 13Neoplasm Metastasis 13Esophageal Neoplasms 13Neoplasms 12Uterine Cervical Neoplasms 11Carcinoma, Ovarian Epithelial 10Head and Neck Neoplasms 7Recurrence 6Carcinoma 6Colorectal Neoplasms 5Adenocarcinoma 5Uterine Neoplasms 4Small Cell Lung Carcinoma 4Oropharyngeal Neoplasms 4Melanoma 4Carcinoma, Transitional Cell 4Advanced Solid Tumors 4Adenocarcinoma Of Esophagus 4Carcinoma, Squamous Cell 3Carcinoma, Renal Cell 3

Interventions

Paclitaxel 2tremelimumab 1trastuzumab deruxtecan 1poly ICLC 1pembrolizumab 1osimertinib 1eribulin 1durvalumab 1cemiplimab 1Vascular Endothelial Growth Factor A 1Radiotherapy 1Peptides 1Doxorubicin 1Docetaxel 1Carboplatin 1Capecitabine 1Bevacizumab 1Antibodies, Bispecific 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Diabetes Mellitus, Insulin-Dependent, 12 × Paclitaxel × Clear all
NCT05142189 2026-04-14

LuCa-MERIT-1

BioNTech SE

Phase 1 Recruiting
320 enrolled
EndocrineThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

NCT05824975 2024-11-25

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

GI Innovation, Inc.

Phase 1/2 Recruiting
358 enrolled
DermatologicGastrointestinalGenitourinarySarcoma

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡